stoxline Quote Chart Rank Option Currency Glossary
  
Enanta Pharmaceuticals, Inc. (ENTA)
17.46  0.93 (5.63%)    03-28 16:00
Open: 16.71
High: 17.76
Volume: 299,052
  
Pre. Close: 16.53
Low: 16.5
Market Cap: 369(M)
Technical analysis
2024-03-28 4:51:07 PM
Short term     
Mid term     
Targets 6-month :  20.74 1-year :  24.22
Resists First :  17.76 Second :  20.74
Pivot price 14.84
Supports First :  14.51 Second :  12.5
MAs MA(5) :  15.69 MA(20) :  15
MA(100) :  11.67 MA(250) :  17.1
MACD MACD :  0.6 Signal :  0.4
%K %D K(14,3) :  87.2 D(3) :  65.2
RSI RSI(14): 70.9
52-week High :  41.45 Low :  8.07
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ENTA ] has closed It is unclear right now based on current values. 85.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.79 - 17.86 17.86 - 17.93
Low: 16.33 - 16.4 16.4 - 16.48
Close: 17.34 - 17.47 17.47 - 17.6
Company Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Headline News

Fri, 29 Mar 2024
Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Target Price at $19.33 - Defense World

Tue, 26 Mar 2024
Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.33 - MarketBeat

Tue, 26 Mar 2024
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Hold” by Brokerages - Defense World

Tue, 19 Mar 2024
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Position Boosted by Walleye Capital LLC - MarketBeat

Tue, 19 Mar 2024
Should You Hold Enanta Pharmaceuticals Inc (ENTA) Stock Tuesday? - InvestorsObserver

Wed, 06 Mar 2024
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 21 (M)
Shares Float 14 (M)
Held by Insiders 6 (%)
Held by Institutions 100.5 (%)
Shares Short 2,090 (K)
Shares Short P.Month 1,840 (K)
Stock Financials
EPS -6.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.06
Profit Margin -187.8 %
Operating Margin -193.8 %
Return on Assets (ttm) -22.9 %
Return on Equity (ttm) -56.2 %
Qtrly Rev. Growth -23.8 %
Gross Profit (p.s.) 0
Sales Per Share 3.47
EBITDA (p.s.) -6.6
Qtrly Earnings Growth 0 %
Operating Cash Flow -93 (M)
Levered Free Cash Flow -15 (M)
Stock Valuations
PE Ratio -2.66
PEG Ratio 0
Price to Book value 1.92
Price to Sales 5.01
Price to Cash Flow -4
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android